News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Staff June 25, 2022 Iframe sync Post navigation Previous: Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext: Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron More Stories Clinical Trial Healthcare News Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness Staff December 22, 2025 Clinical Trial Healthcare News Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness Staff December 22, 2025 Cancer Healthcare News AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference Staff December 22, 2025
